FEATURED

Selinexor and Multiple Myeloma

Early preclinical and clinical data have shown that selinexor has broad activity against multiple hematologic malignancies and notable antimyeloma activity.

Depression as a Side Effect

Researchers are promoting physician and patient awareness about the potential tie between depression and certain therapies.

Fact Sheet: Psychotherapy and Cancer

Some data suggest that psychotherapy may benefit patients with cancer, but higher-quality research is needed.

Ask the Experts: STS Clinical Insights

Cancer Therapy Advisor asked 2 experts to weigh in on the latest clinical insights into soft tissue sarcoma.

Ask the Experts: Waldenström Macroglobulinemia

Cancer Therapy Advisor asked 3 experts to weigh in on recommended treatment modalities for patients with Waldenström macroglobulinemia.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

Selinexor and Multiple Myeloma

Selinexor and Multiple Myeloma

Early preclinical and clinical data have shown that selinexor has broad activity against multiple hematologic malignancies and notable antimyeloma activity.

Depression as a Side Effect: Exploring a Link Between Certain Cancer Treatments and Mental Health

Depression as a Side Effect: Exploring a Link Between Certain Cancer Treatments and Mental Health

Researchers are promoting physician and patient awareness about the potential tie between depression and certain therapies.

Tapping Social Media for Skin Cancer Prevention: What You Can Do

Tapping Social Media for Skin Cancer Prevention: What You Can Do

Any images and personal stories that remind people about skin cancer, what to look for, even scars after surgery, really help save lives.

Re-treatment With Checkpoint Inhibitors in Some Patients with NSCLC May Be Feasible

Re-treatment With Checkpoint Inhibitors in Some Patients with NSCLC May Be Feasible

Even after an adverse event due to treatment with a checkpoint inhibitor, some patients may benefit from re-treatment with drugs from this class.

IL-23 Drives Castration-Resistant Prostate Cancer

IL-23 Drives Castration-Resistant Prostate Cancer

A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs